首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1547592

全球凝血酶原复合浓缩物市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

Global Prothrombin Complex Concentrate Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 171 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

预计到 2032 年，全球凝血酶原复合浓缩物市场的市场规模将从 2023 年的 8,5551 万美元达到近 9,1094 万美元，2024-2032 年研究期间复合年增长率为 0.7%。

凝血酶原复合物浓缩物是一种用作药物的止血血液製品。它由凝血因子 II、IX、X，有时还有凝血因子 VII 组成。该浓缩物能够逆转华法林和其他维生素 K 抗凝血剂的作用。它用于患有凝血功能障碍的人的严重出血病例或此类患者接受紧急手术治疗时。它也用于因先天性、肝病或血友病而缺乏一种凝血因子的人。它是透过直接缓慢注射到人类静脉中进行给药的。它是透过对大量血浆池的冷沉淀上清液进行离子交换色谱法并去除抗凝血酶和因子 XI 来产生的。

市场动态

出血性疾病盛行率的增加和政府对创新医疗疗法的批准放宽是有利于市场成长的驱动因素。由于 PCC 的高临床效率，用于治疗外科手术期间不必要的过度出血的需求不断增长，这将有利于市场的成长。华法林疗法的日益使用以及凝血酶原复合物在快速逆转华法林相关颅内出血患者凝血障碍方面的高效作用将促进市场成长。增加对治疗凝血障碍新药研发的投资以及改善医疗基础设施将是市场的助推器。缺乏认识和这些药物的副作用可能会对市场成长产生沉重影响。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对凝血酶原复合浓缩物全球市场的每个细分市场进行了包容性评估。凝血酶原复合浓缩物产业的成长和趋势为本研究提供了整体方法。

市场区隔

凝血酶原复合浓缩物市场报告的这一部分提供了国家和区域层面的细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人口统计数据以及即将到来的机会。

按产品分类

三因素PCC
4因素PCC

按申请

后天性凝血因子缺乏症
先天性凝血因子缺乏症
其他的

按最终用途

医院及门诊手术中心
专科诊所
其他的

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲的凝血酶原复合浓缩物市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。凝血酶原复合浓缩物市场的主要参与者包括 CSL、Octapharma AG、Kedrion、武田药品工业株式会社、泰邦生物集团有限公司、Sanquin、Grifols、SA、Biotest AG、Abeona Therapeutics Inc.、Insud Pharma。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 9 章：凝血酶原复合物浓缩物公司的竞争格局

凝血酶原复合物浓缩物市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 10 章：公司简介

顶级公司市占率分析
市场集中度
CSL

公司概况
公司收入
产品
最新动态

Octapharma AG

公司概况
公司收入
产品
最新动态

Kedrion

公司概况
公司收入
产品
最新动态

Takeda Pharmaceutical Company Limited.

公司概况
公司收入
产品
最新动态

Taibang Biological Group Co. Ltd.

公司概况
公司收入
产品
最新动态

Sanquin

公司概况
公司收入
产品
最新动态

Grifols

公司概况
公司收入
产品
最新动态

公司概况
公司收入
产品
最新动态

Biotest AG

公司概况
公司收入
产品
最新动态

Abeona Therapeutics Inc.

公司概况
公司收入
产品
最新动态

Insud Pharma

公司概况
公司收入
产品
最新动态

註 - 在公司概况中，财务详细资讯和最新发展视情况而定，或对私人公司而言可能不包括在内

简介目录图表

Product Code: VMR11214580

The global demand for Prothrombin Complex Concentrate Market is presumed to reach the market size of nearly USD 910.94 Million by 2032 from USD 855.51 Million in 2023 with a CAGR of 0.7% under the study period 2024-2032.

Prothrombin complex concentrate is a hemostatic blood product used as medication. It is made up of blood clotting factors II, IX, X, and sometimes factor VII. This concentrate has the ability to reverse the effects of warfarin and other vitamin K anticoagulants. It is used in significant bleeding cases in people with coagulopathy or when such patients undergo an emergency operation treatment. It is also used in people with a deficiency of one of the clotting factors because of congenital, liver disease, or hemophilia. It is administered using a slow injection directly into the human vein. It is produced by the ion-exchange chromatography of the cryoprecipitate supernatant of large plasma pools and antithrombin and factor XI removal.

MARKET DYNAMICS

The increased prevalence of bleeding disorders and eased government approval for innovative medical therapies are few driving factors favoring the market growth. The rising demand for PCC for treating unwanted excessive bleeding during surgical procedures due to its high clinical efficiency will benefit the market's growth. The growing use of warfarin therapy and the high efficiency of prothrombin complex concentrates in rapidly reversing coagulopathy in patients with warfarin-related intracranial hemorrhage will enhance the market growth. Increased investments in the research and development of new drugs to treat blood clotting disorders and improving healthcare infrastructure will be a market booster. Lack of awareness and the side effects of these medications can have a burdening impact on market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Prothrombin Complex Concentrate. The growth and trends of Prothrombin Complex Concentrate industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Prothrombin Complex Concentrate market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

3-factor PCC
4-factor PCC

By Application

Acquired Coagulation Factor Deficiency
Congenital Coagulation Factor Deficiency
Others

By End-use

Hospital & Ambulatory Surgical Centers
Specialty Clinics
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Prothrombin Complex Concentrate market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Prothrombin Complex Concentrate market include CSL, Octapharma AG, Kedrion, Takeda Pharmaceutical Company Limited., Taibang Biological Group Co. Ltd., Sanquin, Grifols, S.A., Biotest AG, Abeona Therapeutics Inc., Insud Pharma. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. PROTHROMBIN COMPLEX CONCENTRATE - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By End-use
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL PROTHROMBIN COMPLEX CONCENTRATE MARKET ANALYSIS BY PRODUCT

5.1. Overview By Product
5.2. Historical and Forecast Data
5.3. Analysis By Product
5.4. 3-factor PCC Historic and Forecast Sales By Regions
5.5. 4-factor PCC Historic and Forecast Sales By Regions

6. GLOBAL PROTHROMBIN COMPLEX CONCENTRATE MARKET ANALYSIS BY APPLICATION

6.1. Overview By Application
6.2. Historical and Forecast Data
6.3. Analysis By Application
6.4. Acquired Coagulation Factor Deficiency Historic and Forecast Sales By Regions
6.5. Congenital Coagulation Factor Deficiency Historic and Forecast Sales By Regions
6.6. Others Historic and Forecast Sales By Regions

7. GLOBAL PROTHROMBIN COMPLEX CONCENTRATE MARKET ANALYSIS BY END-USE

7.1. Overview By End-use
7.2. Historical and Forecast Data
7.3. Analysis By End-use
7.4. Hospital & Ambulatory Surgical Centers Historic and Forecast Sales By Regions
7.5. Specialty Clinics Historic and Forecast Sales By Regions
7.6. Others Historic and Forecast Sales By Regions

8. GLOBAL PROTHROMBIN COMPLEX CONCENTRATE MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE PROTHROMBIN COMPLEX CONCENTRATE COMPANIES

9.1. Prothrombin Complex Concentrate Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF PROTHROMBIN COMPLEX CONCENTRATE INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. CSL
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Octapharma AG
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Kedrion
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Takeda Pharmaceutical Company Limited.
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Taibang Biological Group Co. Ltd.
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Sanquin
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Grifols
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. S.A.
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Biotest AG
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Abeona Therapeutics Inc.
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. Insud Pharma
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments